Catalyst
Slingshot members are tracking this event:
XARELTO (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| JNJ |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 27, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Xarelto, Rivaroxaban, Cardiovascular Events, Peripheral Artery Disease, Phase 3 Study
